Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 9;53(2):250–263. doi: 10.1038/s12276-021-00564-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 8 — a R-PFI inhibited Acta1 promoter activity in a dose-dependent fashion. b Representative gel showing the ChIP assay results. R-PFI attenuated the binding of SRF to the distal SRE in the Acta1 gene promoter. c Quantification results of the ChIP analysis. d Quantitative RT-PCR results showing that R-PFI abolished the increases in Acta1 and Myogenin mRNAs induced by DM for 3 days. e R-PFI blocked the increases in the amounts of ACTA1, MCK, and Myogenin induced by DM for 3 days. f Immunofluorescence images of α-MHC. g Multinucleated cell count. * and ^@p < 0.05; ** and ^@@p < 0.01. h Working hypothesis: KDM2B inhibits skeletal muscle differentiation by inhibiting SRF-induced transactivation of skeletal muscle genes. KDM2B directly binds to SRF to demethylate K165, which results in the detachment of SRF from the SRE in skeletal muscle-specific genes. SET7 counteracts KDM2B by methylating SRF K165.